Ken Griffin’s MapLight Therapeutics MPLT Stock Holding History

Ken Griffin’s Portfolio MPLT Stock Details MPLT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-190,139	Closed	-$3.34M	–	14822
2025 Q4	$3.34M	Buy	+190,139	New	+$3.19M	﹤0.01%	4969

Other funds holding MPLT

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return

NFGH

Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Ken Griffin's MPLT Position: Q1 2026 in Review

Ken Griffin sold out of MapLight Therapeutics (MPLT) in Q1 2026, closing a stake of 190,139 shares — an estimated $3.34M sold.

Ken Griffin first reported a position in MPLT in Q4 2025 and held it in 1 quarter. The position peaked at $3.34M in Q4 2025. 81 funds tracked by Wall St. Rank hold MPLT as of Q1 2026.

Ken Griffin reported no remaining MapLight Therapeutics position as of Q1 2026 after selling out during the quarter.
Ken Griffin sold 190,139 MapLight Therapeutics shares in Q1 2026, an estimated $3.34M.
Ken Griffin first reported a position in MapLight Therapeutics in Q4 2025 and held it in 1 quarter.
Ken Griffin's MapLight Therapeutics position peaked at $3.34M in Q4 2025.
81 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.